- DehydraTECH™ has been shown to improve the taste, smell, bioabsorption and bioavailability of high performance ingestible consumer products
- Lexaria is working to eliminate negative side effects and enhance the healthy benefits of a variety of bioactive compounds
- Research being conducted for healthier oral ingestion of vitamins, nicotine and opioids
DehydraTECH™ is a unique enabling technology from Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) that increases the absorption rate of edible ingestion, delivering five to 10 times more of active ingredients than traditional edibles. This technology is not a competing technology but rather a complementary layer that provides a versatile range of commercial applications. LXRP is the only company in the world that has been awarded a patent for the improved (oral or ingestible) delivery of all non-psychoactive cannabinoids in the U.S. and Australia, and the company has 40 more patents pending worldwide. DehydraTECH™ is patented or patent pending for use with a broad range of bioactive molecules. There are many potential uses for this technology, which aims to enhance ingestible products in terms of taste, smell, speed of action, bioabsorption and bioavailability.
The process by which compounds are processed with LXRP’s DehydraTECH™ creates a flavorless, odorless product. Due to this process, manufacturers can avoid the use of artificial sweeteners and still provide a low-sugar, low-calorie product that’s void of unpleasant tastes. Using a variety of long and medium chain fatty acids, this technology allows for the control of when and how the product is absorbed into the body. The tech speeds up the absorption method, delivering the product to where it is needed. Though high-tech, the method is cost-effective, and, due to its increased potency, it requires smaller quantities to incorporate into food, beverages and pills.
The commercial applications of DehydraTECH™ reach beyond cannabinoids. This oral product format allows for a healthier alternative to smoking or vaping practices for both cannabis and nicotine users. The use of this technology for nicotine users holds the potential to shift demand away from smoking cigarettes. The primary cause of illness and death for smokers is not the nicotine, but rather the toxins and carcinogens in the tobacco smoke. LXRP is seeking third-party partnerships within the tobacco industry in order to eliminate the need to light up (http://ibn.fm/1wlln).
In addition, this technology is being used to help deliver fat-soluble vitamins and non-steroidal anti-inflammatory agents (NSAIDs) into orally ingestible products with a greater absorbency and higher performance. The commercial applications are promising as LXRP tests ways to combat the negative side effects and enhance the healthy benefits of a variety of bioactive compounds. While previous studies have focused primarily on cannabinoid applications, LXRP is conducting research for other bioactive compounds such as vitamins, nicotine and NSAIDs.
For more information, visit the company’s website at www.LexariaBioscience.com
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.